Jan 8, 2020 by Brian Orelli, PhDAbbVie Lays Out Plans to Integrate AllerganThe company is leaving the aesthetics unit largely intact.
Jan 8, 2020 by Brian Orelli, PhDHere's Why Applied Therapeutics Rocketed Higher TodayStellar results from a phase 2 study have investors excited about the biotech's prospects.
Jan 7, 2020 by Brian Orelli, PhDClovis Oncology Reports Preliminary Fourth Quarter Sales of Rubraca and Sells Additional SharesGrowth of the cancer drug has slowed, but an expanded approval could increase future sales.
Jan 6, 2020 by Brian Orelli, PhDFibroGen Appoints Enrique Conterno as Its New CEOThe former Eli Lilly executive will be tasked with launching the biotech's anemia drug roxadustat.
Jan 2, 2020 by Brian Orelli, PhDHere's Why Novocure Slipped Lower TodayAn analyst downgrade puts short-term pressure on the medical-device company's share price.
Jan 2, 2020 by Brian Orelli, PhDHere's Why Shares of DURECT Plummeted TodayThe biotech's midstage study of DUR-928 failed, but the drug isn't dead yet.
Dec 31, 2019 by Brian Orelli, PhDHere's Why DURECT Jumped Higher TodayInvestors jump in ahead of a binary event.
Dec 18, 2019 by Brian Orelli, PhDHere's Why Solid Biosciences Stock Got Hammered TodayEarly data for its side-effect-ridden gene therapy SGT-001 doesn't look very promising.
Dec 17, 2019 by Brian Orelli, PhDHere's Why Proteostasis Therapeutics Stock Plummeted TodayPositive clinical trial data wasn't positive enough.
Dec 16, 2019 by Brian Orelli, PhDHere's Why Avadel Pharmaceuticals Dropped TodayThe biotech received an FDA approval, but the launch timing is uncertain.
Dec 11, 2019 by Brian Orelli, PhDHere’s Why Momenta Pharmaceuticals Stock Dropped TodayInvestors are worried about the biotech raising cash.
Dec 10, 2019 by Brian Orelli, PhDHere’s Why bluebird bio Shares Jumped Almost 12% TodaySolid data from the biggest blood disease meeting of the year has the biotech flying high.
Dec 9, 2019 by Brian Orelli, PhDWhy Diplomat Pharmacy Crashed (for a Final Time?) TodayThe beleaguered specialty pharmacy is being "taken under."
Dec 4, 2019 by Brian Orelli, PhDHere’s Why ImmunoGen Jumped 12.4% TodayInvestors in the cancer-focused biotech are hoping for good news next week.
Dec 4, 2019 by Brian Orelli, PhDHere’s Why Qiagen Skyrocketed Over 43% in NovemberBuyout speculation buoys the test maker.
Nov 27, 2019 by Brian Orelli, PhDHere's Why Diplomat Pharmacy Jumped Higher TodayMore volatility for the beleaguered specialty pharmacy and pharmacy benefit manager.
Nov 27, 2019 by Brian Orelli, PhDAgios Pharmaceuticals Raised $294 Million to Fight Cancer and Rare Genetic Diseases: What It Means for InvestorsThe cash will help the biotech get to profitability.
Nov 26, 2019 by Brian Orelli, PhDHere’s Why Aurinia Pharmaceuticals Stock Jumped Higher TodayResults of a phase 3 clinical trial are imminent for the biotech.
Nov 26, 2019 by Brian Orelli, PhDCRISPR vs. Gene Therapy Round 1: What Investors Need to KnowThere’s still a long way to go, but the newcomer is off to a good start.
Nov 26, 2019 by Brian Orelli, PhDReata Pharmaceuticals Just Raised $505 Million to Treat Orphan Diseases: What it Means for InvestorsThe capital sets the biotech up nicely to launch two successful drugs.
![Enrique-Conterno[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F552569%2Fenrique-conterno1.jpg&w=384&op=resize)
